Navigation Links
Drug TEMODAL and Radiotherapy for brain cancer treatment

Canada Health Government has approved the drug TEMODAL in combination with Radiotherapy for treating patients with glioblastoma multiforme brain cancer. // The drug TEMODAL that contains Temozolomide is produced by Schering-Plough Corporation and is used in treating two forms of brain cancer Glioblastoma multiforme and anaplastic astrocytoma.

Clinical study using the drug TEMODAL was tested on newly diagnosed glioblastoma multiforme patients by researchers from National Cancer Institute, Canada and European organization for Research and Treatment of Cancer and they found the drug to be effective in controlling the growth of malignant cells in the brain, by producing cytotoxic effect on cancer cells and prevents replication and production of cancer cells. Researchers have found on a clinical study on 573 patients that a combination of drug TEMODAL and radiotherapy in brain cancer patients reduces the tumor burden and significantly increases the survival of the cancer patients. The drug has been shown very effective but is found to cause mild side effects of myelosuppression in patients and the researchers have reported the results of their study in the Journal the New England Journal of Medicine.


'"/>




Page: 1

Related medicine news :

1. Radiotherapy helps in colon cancer
2. Link between Obesity and Post-Radiotherapy Outcome in Prostate Cancer Patients
3. Booster Dose Of Radiotherapy Beneficial In Early Breast Cancer
4. Patients Receiving Treatment with Radiotherapy Might trigger Security Alarms
5. Recurrence of bowel cancer cut down by Radiotherapy
6. Radiotherapy Centers in Scotland Undergo Inspection
7. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
8. Two doctors suspended for wrong brain surgery
9. The brain loves a surprise
10. Increase in sugar...decrease in brain function!!!
11. Alcohol shrinks brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... , ... December 08, 2016 , ... With the increasing ... the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about the ... the dental implant and prosthetic market in the U.S. is projected to reach $6.4 ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... Bodycad announced it has been awarded ... reproducibility and speed for 3D constructs via MRI ... orthopaedic applications. These patents are critical to the ... based on each patient,s distinct anatomy. ... the world,s first suite of orthopaedic CAD/CAM software. ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: